Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04173533 | Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT(AMADEUS) | completed | Phase 3 | 326 | University of BirminghamOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT03480360 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | completed | Phase 3 | 21 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jul 17, 2026 |
| clinicaltrials |
| NCT00093470 | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | completed | Phase 3 | 144 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT02730299 | Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS | completed | Phase 3 | 125 | Gamida Cell ltdINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT03594149 | Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients(AZABAC) | completed | Phase 3 | 60 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT03745716 | APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) | completed | Phase 3 | 154 | Aprea TherapeuticsINDUSTRY | 2 | Mar 18, 2025 | clinicaltrials |
| NCT03092674 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 / Phase 3 | 76 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2025 | clinicaltrials |
| NCT02907359 | Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs | completed | Phase 3 | 417 | Astex Pharmaceuticals, Inc.INDUSTRY | 14 | Aug 27, 2024 | clinicaltrials |
| NCT03306264 | Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML | completed | Phase 3 | 227 | Astex Pharmaceuticals, Inc.INDUSTRY | 10 | Aug 27, 2024 | clinicaltrials |
| NCT03275636 | Haploidentical Donor vs mMUD in Hematological Malignancies(HAMLET) | completed | Phase 2 / Phase 3 | 98 | DKMS gemeinnützige GmbHOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT00043381 | Decitabine Versus Supportive Care in Adults With Advanced-stage MDS | completed | Phase 3 | 160 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03959241 | TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)(1703/1801) | completed | Phase 3 | 431 | Medical College of WisconsinOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT01288378 | Empirical Versus Preemptive Antifungal Therapy | completed | Phase 3 | 556 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Dec 11, 2023 | clinicaltrials |
| NCT01951885 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | completed | Phase 3 | 101 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT00046930 | Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia | completed | Phase 3 | 449 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jul 5, 2023 | clinicaltrials |
| NCT02942173 | CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT | completed | Phase 2 / Phase 3 | 150 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT00354120 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant(GLOBAL) | completed | Phase 2 / Phase 3 | 121 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT02345850 | Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301) | completed | Phase 3 | 346 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 7, 2023 | clinicaltrials |
| NCT00406393 | Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402) | completed | Phase 3 | 304 | Medical College of WisconsinOTHER | 2 | Jan 4, 2023 | clinicaltrials |
| NCT00450450 | Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | completed | Phase 3 | 27 | Children's Oncology GroupNETWORK | 1 | Apr 28, 2022 | clinicaltrials |
| NCT02566395 | Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies | completed | Phase 3 | 10 | Northwell HealthOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT00369317 | Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 3 | 205 | Children's Oncology GroupNETWORK | 4 | Jan 28, 2022 | clinicaltrials |
| NCT02214407 | Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML(GFM-DAC-CMML) | completed | Phase 3 | 170 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT00412360 | Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501) | completed | Phase 3 | 224 | Medical College of WisconsinOTHER | 3 | Oct 28, 2021 | clinicaltrials |
| NCT00003816 | Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer | completed | Phase 2 / Phase 3 | 361 | Roswell Park Cancer InstituteOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT00469144 | IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | completed | Phase 3 | 233 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT00006083 | Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter | completed | Phase 3 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT01602211 | INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant(INSPIRE) | completed | Phase 3 | 1,600 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT00822393 | Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) | completed | Phase 3 | 570 | medac GmbHINDUSTRY | 6 | Jul 30, 2020 | clinicaltrials |
| NCT00750009 | Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial | completed | Phase 3 | 583 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts(ONTIME) | completed | Phase 3 | 299 | Traws Pharma, Inc.INDUSTRY | 6 | Jun 30, 2020 | clinicaltrials |
| NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | completed | Phase 3 | 67 | Traws Pharma, Inc.INDUSTRY | 8 | Jun 30, 2020 | clinicaltrials |
| NCT00003687 | Treatment for Chronic Pain in Patients With Advanced Cancer | completed | Phase 3 | 87 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00887068 | Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | completed | Phase 3 | 187 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT01295710 | Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) | completed | Phase 3 | 260 | Neovii BiotechINDUSTRY | 2 | Apr 9, 2019 | clinicaltrials |
| NCT00656448 | A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS | completed | Phase 3 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT00516503 | Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer | completed | Phase 3 | 208 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT00044486 | Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) | completed | Phase 3 | 602 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 10, 2017 | clinicaltrials |
| NCT00755040 | Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder | completed | Phase 3 | 164 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT00719563 | American Ginseng in Treating Patients With Fatigue Caused by Cancer | completed | Phase 3 | 364 | Alliance for Clinical Trials in OncologyOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT00121303 | Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 3 | 600 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00006348 | Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment | completed | Phase 3 | 100 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00000591 | T-Cell Depletion in Unrelated Donor Marrow Transplantation | completed | Phase 3 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 0 | Apr 15, 2016 | clinicaltrials |
| NCT01751867 | An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome | completed | Phase 3 | 135 | Xian-Janssen Pharmaceutical Ltd.INDUSTRY | 1 | Apr 5, 2016 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT00005866 | S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia | completed | Phase 3 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Mar 6, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2026source: clinicaltrials